Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

20
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
20
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

101
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
101
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

173
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
173
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

138
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
138
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

88
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
88
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

257
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and non-clinical use of MDMA.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

Journal of affective disorders·2026
Same author

MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al.

The British journal of psychiatry : the journal of mental science·2026
Same author

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM.

The British journal of psychiatry : the journal of mental science·2026
Same author

MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial.

Journal of psychiatric research·2025
Same author

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.

The British journal of psychiatry : the journal of mental science·2025

Related Experiment Video

Updated: May 20, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.1K

Ketamine in treatment-resistant depression

Mark Berthold-Losleben, Ingrid Autran, Rikke Lise Steen Folstad

    Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
    |March 27, 2025
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    13.8K
    Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
    09:30

    Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

    Published on: October 4, 2016

    22.2K

    Related Experiment Videos

    Last Updated: May 20, 2025

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    28.1K
    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    13.8K
    Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
    09:30

    Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

    Published on: October 4, 2016

    22.2K